Prediction of Positions of Active Compounds Makes It Possible To Increase Activity in Fragment-Based Drug Development

Yoshifumi Fukunishi 1,2

1 Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST)/ 2-3-26, Aomi, Koto-ku, Tokyo 135-0064, Japan; E-Mail: y-fukunishi@aist.go.jp; Tel.: +81-3-3599-8290; Fax: +81-3-3599-8099

2 Pharmaceutical Innovation Value Chain, BioGrid Center Kansai/ 1-4-2 Shinsenri-Higashimachi, Toyonaka, Osaka 560-0082, Japan

Received: 28 March 2011; in revised form: 17 May 2011 / Accepted: 20 May 2011 / Published: 20 May 2011

Abstract: We have developed a computational method that predicts the positions of active compounds, making it possible to increase activity as a fragment evolution strategy. We refer to the positions of these compounds as the active position. When an active fragment compound is found, the following lead generation process is performed, primarily to increase activity. In the current method, to predict the location of the active position, hydrogen atoms are replaced by small side chains, generating virtual compounds. These virtual compounds are docked to a target protein, and the docking scores (affinities) are examined. The hydrogen atom that gives the virtual compound with good affinity should correspond to the active position and it should be replaced to generate a lead compound. This method was found to work well, with the prediction of the active position being 2 times more efficient than random synthesis. In the current study, 15 examples of lead generation were examined. The probability of finding active positions among all hydrogen atoms was 26%, and the current method accurately predicted 60% of the active positions.

Keywords: FBDD; protein-compound docking; drug design; fragment growth; virtual screening; structure-based drug screening
1. Introduction

In the drug-development process, after getting a set of seed compounds, the next step is lead generation. The major purpose of the lead generation is enhancement of the affinity of the seed compound to the target protein. In the lead generation process, the useless portion of the seed compound is reduced, while the necessary part is attached to the seed compound. In some cases, the scaffold is replaced by another scaffold. Usually, the QSAR method is applied to the seed and its derivatives to increase the affinity. The protein-compound complex structure is also analyzed in the lead generation.

Recently, fragment-based drug development (FBDD) has become popular. In FBDD, the most frequently used techniques are fragment linking, fragment evolution, fragment merging, and fragment growth [1-7]. In the fragment growth technique, which is the most popular method, additional fragments are attached to the seed compound by chemical modification. In the FBDD process, reducing the size of the seed compound is not the main tactic. Similar to conventional lead generation, the QSAR method is applied to the seed and its derivatives to increase the affinity, and the protein-compound complex structure is also analyzed in the lead generation.

In fragment evolution, one of the most important issues is predicting the position that can increase the affinity by chemical modification. In the lead generation process, the number of atoms is increased by 1.5 times from the seed compound to the lead compound, and the hydrophobicity is increased by the addition of hydrophobic groups to the seed compound [1]. If the protein-ligand complex structure is predicted by a docking study, the information can be helpful in designing the lead compound. However, prediction of the protein-ligand complex structure is difficult. Usually, the prediction accuracy of the cross-docking test by docking programs is approximately 20-30% [8, 9].

Especially in the case of the FBDD, a docking study of fragments is difficult, since the fragments are too small to obtain a stable protein-compound complex structure by docking study. Previously, we proposed the FSRG (fragment screening by replica generation) method, in which virtual side chains are attached to the fragments to enable the docking study [10]. In the current study, we developed a computational method that can predict position and increase the affinity by chemical modification for the fragment evolution method.

There have been many de novo design programs reported, such as LEGEND [11], LUDI [12], SPROUT [13], HOOK [14], GrowMol [15], PRO-LIGAND [16], CONCERT [17], LEA3D [18] and AutoGrow [19]. The differences between the current study and the previous studies are two points. The first point is that the previous studies reported the successful designed compounds for only one or two targets and the success rate was unclear. In the current study, the software was applied to the 15 targets and the success rate was evaluated. The second point is that the previous de novo studies overspecify the designed ligands. The designed compounds frequently meet the problem of synthetic accessibility. Some programs generate the compounds based on the known active compounds and these programs added chemical modification onto the given scaffolds. In some cases, medicinal chemists want to design ligands considering the availability of reagents and just want to know which position of compound must be modified. Thus, in the current study, the program was designed to suggest only the position of compound, which should be modified.
2. Method

Starting from an active fragment (seed compound) and the 3D structure of the target protein, we try to predict which atom should be modified chemically to increase the activity. In the current study, only hydrogen atoms and fluorine atoms were modified. While there are numerous varieties of chemical modifications, only a limited number of side chains (less than 80) were used in the current study for chemical modification. A set of virtual compounds were generated from the active fragment by artificial chemical modification, and the subsequent docking study was carried out to rank the virtual compounds according to the docking score. The modified position of the top-ranked virtual compound was predicted as the active position. The details of this method are described below.

All hydrogen atoms and fluorine atoms of the active fragment were replaced by side chains, one by one. The side chains are small groups (methyl, ethyl, phenyl, etc) and their derivatives. Three sets of side chains (sets A, B, and C) were prepared, and these sets, A, B, and C, consisted of 78, 38, and 25 side chains, respectively. These side chains, which are summarized in Figure 1, are small hydrocarbons including up to two aromatic rings, and they do not include heteroatoms. The side chains are prepared manually and arbitrary. These side chains were summarized in the supporting information.

**Figure 1.** Side chain sets A, B, and C. All sets consist of the compounds 1-9 and their derivatives. **Set A:** For compound 1-9, R or one of the R's is directly attached to the active fragment and the other R's are replaced by H. In addition, for compound 8-9, R or one of the R's is replaced by -CH2-R, -CH2-CH2-R, -CH=CH-R (R is the active fragment) and the other R's are replaced by H. **Set B:** For compound 1-9, R or one of the R's is directly attached to the active fragment and the other R's are replaced by H. In addition, for compound 8-9, R or one of the R's is replaced by -CH2-R, -CH2-CH2-R (R is the active fragment) and the other R's are replaced by H. **Set C:** For compound 1-9, R or one of the R's is directly attached to the active fragment and the other R's are replaced by H. In addition, for compound 8-9, R or one of the R's is replaced by -CH2-R (R is the active fragment) and the other R's are replaced by H.
These side chains are introduced into the active fragment by the BindMol program, which is an in-house program. If the attached side chain comes into contact with an atom of the seed compound (intra-molecular atomic conflict), such a compound is not generated. The atomic coordinates of the generated virtual compound are optimized by an energy minimization calculation in vacuum. The Cosgene/myPresto program is used for energy minimization with a general AMBER force field, and the dielectric constant is set to 4R, where R is the inter-atomic distance [20]. The atomic charges are calculated by the Gasteiger method [21, 22].

The protein-compound docking simulation is performed with the Sievgene/myPresto program [23]. Each generated virtual compound is docked to the target protein by the flexible docking method and the affinity of each virtual compound is evaluated by the docking score. The docking pocket of each protein was indicated by the coordinates of the original ligand. Hydrogen atoms were added to the coordinates by tplgene/myPresto. The atomic charges of the proteins were the same as those of AMBER parm99 [24]. For flexible docking, the Sievgene program generated up to 100 conformers for each compound, and a 120x120x120 grid is applied to the scoring grid. The atomic coordinates of the target protein were fixed. The protonated states of the proteins and compounds are the dominant ion forms at pH 7. Finally, the virtual compounds are sorted according to their docking scores. The modified position of the top ranked compound among all virtual compounds is the predicted active position.

3. Results

3.1. Single target protein structure was used

We collected 15 FBDD examples from literature reports [25-39]. Each example consisted of a seed compound, lead compounds derived from the seed compound, and 3D coordinates of the target protein. The seed compounds were suggested by the literature [1,40]. The current procedure was applied to these 15 target proteins. These target names are summarized in Table 1, along with the number of virtual compounds generated for each target. Figure 2 shows the seed compounds of these target proteins. The active positions of these compounds are also shown in Figure 2. Figure 2 also shows the predicted active positions by the current calculation. The probability of predicting accurate active positions is summarized in Table 2. On average, the probability of finding active positions among all hydrogen atoms was 26.32% by random prediction. On the other hand, the current method predicted 60.0% of the active positions when side chain set A was used. The prediction is approximately two times more efficient than a random selection of active positions. As far as the second top predicted position is considered in addition to the top ranked position, the probability of finding active positions among all hydrogen atoms was 45.71% by random prediction. On the other hand, the current method predicted 66.67%, 46.67% and 46.67% of the active positions when side chain sets A, B and C were used, respectively. These values were bigger than the probability by the random prediction, but the advantage of the current method is not significant anymore.

The prediction accuracy increased with increases the number of attached side chains. The prediction accuracy obtained with set A was better than that with sets B and C. Thus, the prediction accuracy should be improved by increasing the number of side chains or the variety of side chains.
Table 1. Active position prediction accuracy by the current method.

| Target protein      | PDB ID | No. of H/F \(^{a}\) | No. of active sites \(^{b}\) | No. of compds \(^{c}\) | Rank \(^{d}\) | No. of compds | Rank | No. of compds | Rank |
|---------------------|--------|----------------------|-----------------------------|----------------------|--------------|----------------|------|----------------|------|
| Akt                 | 2UZT   | 17                   | 3                           | 1311                 | 2            | 647            | 2    | 425            | 2    |
| Bcl-XL              | 1YS1   | 10                   | 1                           | 726                  | 1            | 373            | 2    | 245            | 2    |
| CDK2                | 1VYZ   | 12                   | 8                           | 859                  | 1            | 419            | 1    | 274            | 1    |
| DNHA                | 2NM2   | 8                    | 1                           | 618                  | 63           | 302            | 12   | 196            | 12   |
| ERK2                | 2OJG   | 17                   | 8                           | 1159                 | 1            | 583            | 1    | 386            | 1    |
| HSP90               | 1BYQ   | 10                   | 3                           | 695                  | 1            | 344            | 3    | 225            | 3    |
| IMPDH               | 1NF7   | 7                    | 3                           | 469                  | 1            | 230            | 1    | 150            | 1    |
| Janus kinase        | 3JY9   | 10                   | 1                           | 777                  | 28           | 380            | 17   | 248            | 17   |
| KDR                 | 1T46   | 10                   | 3                           | 757                  | 1            | 379            | 1    | 249            | 1    |
| Lactate dehydrogenase | 1ARZ  | 10                   | 1                           | 701                  | 1            | 344            | 9    | 225            | 9    |
| MetAP2              | 1YW7   | 16                   | 2                           | 1273                 | 36           | 627            | 10   | 407            | 10   |
| MMP12               | 1Y93   | 6                    | 3                           | 392                  | 1            | 192            | 1    | 125            | 1    |
| NADP                | 2F10   | 13                   | 6                           | 839                  | 1            | 404            | 3    | 256            | 3    |
| PDE4                | 1MKD   | 14                   | 1                           | 1094                 | 134          | 534            | 33   | 350            | 33   |
| Urokinase           | 1ETF   | 11                   | 1                           | 727                  | 43           | 338            | 31   | 209            | 28   |
| Average             |        |                      |                             |                      |              |                |      | 33.33%         |      |

\(^{a}\) number of H/F atoms of active fragment; \(^{b}\) number of true active positions of active fragment; \(^{c}\) number of generated virtual compounds; \(^{d}\) rank of the virtual compound that precisely predicts the true active position.

**Figure 2.** True active positions and predicted active positions. “R” represents the true active position, and the arrow represents the predicted active position by the current method by using side chain set A.
The used virtual side chains (sets A, B and C) were not hydrophilic groups but hydrophobic groups that were hydrocarbons. In the fragment evolution process, hydrophobic groups are usually added to the active fragment compound to increase the activity [40]. It appears reasonable to use simple hydrophobic groups for chemical modification, while the variations of chemical modification are infinite.

### 3.2. Multiple target structures were used

In addition to the single target protein, multiple target protein structures were examined. These proteins were extracted from the PDB. The used protein structures are summarized in Table 2. Each protein was prepared for docking in the same manner described in the Methods section. The docking

### Table 2. Prediction results with multiple target protein structures.

| Target  | PDB ID       | Rank<sup>a</sup> |
|---------|--------------|------------------|
| Bcl-XL  | 1YS1 1YSG 1YSN 1YSW 2YXJ | 1               |
| ERK2    | 2OJG 2OJI 2OJJ 2OK1         | 1               |
| LFA-1   | 1XDD 1XDG            | 1               |
| MetAP2  | 1YW7 1YW8          | 58              |
| NADP    | 2F10 3JSX           | 1               |
| PDE4    | 1MKD 1Q9M          | 28              |
|         | Average           | 66.67%          |

<sup>a</sup> rank of the virtual compound that precisely predicts the true active position
scores for all protein structures were merged and re-ranked based on the docking score. The results are summarized in Table 2. When side chain set A was used, the prediction accuracy was 66%, which is the same value obtained from the single target protein structure.

3.3. Ranking of true lead compounds

To estimate the limitations of the prediction accuracy, the true lead compounds were added to the virtual compounds. A single target protein structure was used. The compounds were docked to the target protein, and these compounds were ranked according to the docking score. If the docking scores are accurate, the true lead compounds should be ranked at the first positions. The results are summarized in Table 3. The true lead compounds appeared at the first rank with a probability of 60%, while this probability would be 2.8% by random selection. The docking study actually worked, but the prediction was not perfect. This 60% probability should be considered the upper limit of the current prediction method.

| Target protein     | PDB ID | No. of compounds | No. of true leads | Rank |
|--------------------|--------|------------------|-------------------|------|
| Akt                | 2UZT   | 1361             | 50                | 41   |
| Bcl-XL             | 1YS1   | 727              | 1                 | 1    |
| CDK2               | 1VYZ   | 900              | 41                | 1    |
| DNHA               | 2NM2   | 634              | 16                | 1    |
| ERK2               | 2OJG   | 1192             | 33                | 334  |
| HSP90              | 1BYQ   | 699              | 4                 | 1    |
| IMPDH              | 1NF7   | 497              | 28                | 1    |
| JanusKinase        | 3JY9   | 778              | 1                 | 343  |
| KDR                | 1T46   | 805              | 48                | 1    |
| Lactatedehydrogenase | 1ARZ   | 704              | 3                 | 1    |
| MetAP2             | 1YW7   | 1381             | 108               | 1    |
| MMP12              | 1Y93   | 393              | 1                 | 8    |
| NADP               | 2F10   | 867              | 28                | 298  |
| PDE4               | 1MKD   | 1102             | 8                 | 303  |
| Urokinase          | 1ETF   | 754              | 27                | 1    |

Average 2.80% 60.00%

a number of generated virtual compounds; b rank of the virtual compound that precisely predicts the true active position

4. Discussion

On average, the probability of active positions among all hydrogen atoms was 26.32%, and the current method predicted 60.0% of the active positions. Considering that the accuracy of cross-docking by Sievgene is only 25%, the prediction accuracy of the current method is high. Our previous study
shows that the virtual screening of fragment is difficult by docking study but that if a virtual side chain is added to the fragment compound, virtual screening of the modified fragment compound becomes easy [10]. As such, the accuracy is improved by the addition of a virtual side chain to fragment compounds. In the current study, the prediction accuracy would have been improved by the addition of virtual side chains to the active fragment compound.

The prediction accuracy obtained by side chain with set C was much better than that with sets A and B. The difference between the sets was that the side chains of set A included a C=C structure. This structure mimics that of amide or ester structures. Since the major contribution of the sievgene docking score is the ASA term and the electrostatic interaction is not as important, the size and shape of the group/compound is important in the sievgene docking score [10].

The prediction accuracy reached 60%, but no higher. Even if multiple structures were used, the prediction accuracy was not improved. In in-silico drug screening, the ensemble docking method has been used to consider features of protein flexibility such as induced-fitting. In an ensemble docking study, many protein structures are prepared for the docking study and each structure gives an in-silico drug screening result. We can obtain many screening results, but only a limited number of them can be reliable. How to select the reliable screening result from the many results is a serious problem. Ensemble docking studies have shown that the docking score does not consistently provide reliable results or true hit (active) compounds [41-44]. The same phenomenon should have occurred in the current study, and the docking scores were not good enough to predict the active positions.

Since comprehensive chemical modification is almost impossible, the reported active positions should correspond to one of the registered active positions. The same as the probability of true active positions, the accuracy of prediction should be underestimated. That is, even though a true active position is predicted, if the position is not reported (the position is not included in the registered active positions), the prediction is judged to be a failure. These chemical modifications are restricted by the synthetic accessibility, and the analysis of this current study is somewhat ambiguous.

5. Conclusions

We have developed a computational method that predicts the positions of seed compounds that should be chemically modified in the fragment evolution method. In the current method, to predict the active position, all hydrogen atoms are replaced by small side chains. Three sets of side chains were prepared manually. These virtual compounds were docked to a target protein, and the docking scores (affinities) were examined. The hydrogen atom that gave the virtual compound with good affinity was determined to be the active position that should be replaced to generate a lead compound. This method worked well. The prediction of active position was two times more efficient than random synthesis. In the current study, 15 examples of lead generation were examined. The probability of active positions among all hydrogen atoms was 26%, and the current method predicted 60% of the active positions.

Acknowledgements

This work was performed as part of the NEDO project, Development of Basic Technology for Protein Structure Analysis Aimed at Acceleration of Drug Discovery Research, directed by Prof. Haruki Nakamura at the Institute for Protein Research, Osaka University, Japan.
References

1. Orita, M.; Ohno, K.; Niimi, T. Two “Golden ratio” indices in fragment-based drug discovery. Drug Discov. Today 2009, 14, 321-328.
2. Hajduk, P.J.; Huth, J.R.; Fesik, S.W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 2005, 48, 2518-2525.
3. Albert, J.S.; Blomberg, N.; Breeze, A.L.; Brown, A.J.H.; Burrows, J.N.; Edwards, P.D.; Folmer, R.H.A.; Geschwindner, S.; Griffen, E.J.; Kenny, P.W.; Nowak, T.; Olsson, L.L.; Sanganess, H.; Shapiro, A.B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca’s drug discovery programmes. Curr. Topics Med. Chem. 2007, 7, 1600-1629.
4. Erlanson, D.A.; McDowell, R.S.; O’Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
5. Alex, A.A.; Flocco, M.M. Fragment-based drug discovery: What has it achieved so far? Curr. Topics Med. Chem. 2007, 7, 1544-1567.
6. Hajduk, P.J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug. Discov. 2007, 6, 211-219.
7. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A.J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661-3680.
8. Fukunishi, Y.; Nakamura, H. Prediction of protein-ligand complex by docking software guided by other complex structures, J. Mol. Graph. Model. 2008, 26, 1030-1033.
9. Fukunishi, Y.; Nakamura, H. A new method for in-silico drug screening and similarity search using molecular-dynamics maximum-volume overlap (MD-MVO) method. J. Mol. Graph. Model. 2009, 27, 628-636.
10. Fukunishi, Y.; Mashimo, T.; Orita, M.; Ohno, K.; Nakamura, H. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design. J. Chem. Inf. Model. 2009, 49, 925-933.
11. Nishibata, Y.; Itai, A. Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron 1991, 47, 8885-8990.
12. Bohm, H. J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
13. Gillet, V.; Johnson, A. P.; Mata, P.; Sike, S.; Williams, P. SPROUT: A program for structure generation. J. Comput.-Aided Mol. Des. 1993, 7, 127-153.
14. Eisen, M. B.; Wiley, D. C.; Karplus, M.; Hubbard, R. E. HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 1994, 19, 199-221.
15. Bohacek, R. S.; McMartin, C. Multiple highly diverse structures complementary to enzyme binding sites: Results of extensive application of de novo design method incorporating combinatorial growth. J. Am. Chem. Soc. 1994, 116, 5560-5571.
16. Clark, D. E.; Frenkel, D.; Levy, S. A.; Li, J.; Murray, C. W.; Robson, B.; Waszkowycz, B.; Westhead, D. R. PRO-LIGAND: An approach to de novo molecular design. 1. Application to the design of organic molecules. J. Comput.-Aided Mol. Des. 1995, 9, 13-32.
17. Pearlman, D. A.; Murcko, M. A. CONCERTS: Dynamic connection of fragments as an approach to de novo ligand design. *J. Med. Chem.* **1996**, *39*, 1651-1663.

18. Douguet, D.; Munier-Lehmann, H.; Labesse, G.; Pochet, S. LEA3D: a computer-aided ligand design for structure-based drug design. *J. Med. Chem.* **2005**, *48*, 2547-2468.

19. Durrant, J.D.; Amaro, R.E.; McCammon, J.A. AutoGrow: a novel algorithm for protein inhibitor design. *Chem. Biol. Drug Des.* **2009**, *73*, 168-178.

20. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. *J. Comput. Chem.* **2004**, *25*, 1157-1174.

21. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. *Tetrahedron* **1980**, *36*, 3219-3228.

22. Gasteiger, J.; Marsili, M. A new model for calculating atomic charges in molecules. *Tetrahedron Lett.* **1978**, *3181-3184.

23. Fukunishi, Y.; Mikami, Y.; Nakamura, H. Similarities among receptor pockets and among compounds: Analysis and application to in silico ligand screening. *J. Mol. Graph. Model.* **2005**, *24*, 34-45.

24. Case, D.A.; Darden, T.A.; Cheatham, T.E.III.; Simmerling, C.L.; Wang, J.; Duke, R.E.; Luo, R.; Merz, K.M.; Wang, B.; Pearlman, D.A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J.W.; Ross, W.S.; Kollman, P.A. AMBER 8, University of California San Francisco: San Francisco. CA, USA, 2004.

25. Zhu, G.; Gandhi, V.B.; Gong, J.; Thomas, S.; Woods, K.W.; Song, X.; Li, T.; Diebold, R.B.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V.; Johnson, E.F.; Bouska, J.; Olson, A.; Marsh, K.C.; Stoll, V.S.; Mamo, M.; Polakowski, J.; Cambell, T.J.; Martin, R.L.; Gintant, G.A.; Penning, T.D.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. *J. Med. Chem.* **2007**, *50*, 2990-3003.

26. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J.; Krimm, I. Fragment-based deconstruction of Bel-XL inhibitors. *J. Med. Chem.* **2010**, *53*, 2577-2588.

27. Pevarello, P.; Brasca, M.G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B.S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E.L.; Nugent, R.A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K.L.; Clare, P.M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M.A. 3-aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. *J. Med. Chem.* **2004**, *47*, 3367-3380.

28. Sanders, W.L.; Nienaber, V.L.; Lerner, C.G.; McCall, J.O.; Merrick, S.M.; Swanson, S.J.; Harlan, J.E.; Stoll, V.S.; Stamper, G.F.; Betz, S.F.; Condroski, K.R.; Meadows, R.P.; Severin, J.M.; Walter, K.A.; Magdalions, P.; Jakob, C.G.; Wagner, R.; Beutel, B.A. Discovery of potent inhibitors of dihydroneopterin aldolase using crystalLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. *J. Med. Chem.* **2004**, *47*, 1709-1718.

29. Aronov, A.M.; Baker, C.; Bemis, G.W.; Cao, J.; Chen, G.; Ford, P.J.; Germain, U.A.; Green, J.; Hale, M.R.; Jacobs, M.; Janetka, J.W.; Maltais, F.; Martinez-Botella, G.; Namchuk, M.N.; Straub,
J.; Tang, Q.; Xie, X. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. *J. Med. Chem.* 2007, 50, 1280-1287.

30. Huth, J.R.; Park, C. Petros, A.M.; Kunzer, A.R.; Wendt, M.D.; Wang, X.; Lynch, C.L.; Mack, J.C.; Swift, K.M.; Judge. R.A.; Chen, J.; Richardson, P.L.; Jin, S.; Tahir, S.K.; Matayoshi, E.D.; Dorwin, S.A.; Ladror, U.S.; Severin, J.M.; Walter, K.A.; Bartley, D.M.; Fesik, S.W.; Elmore, S.W.; Hajduk, P.L. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. *Chem. Biol. Drug Des.* 2007, 70, 1-12.

31. Beevers, P.E.; Buckley, G.M.; Davies, N.; Fraser, J.L.; Galvin, F.C.; Hannah, D.R.; Haughan, A.F.; Jenkins, K.; Mack, S.P.; Pitt, W.R.; Ratcliffe, A.J.; Richard, M.D.; Sabin, V.; Sharpe, A.; Williams, S.C. Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationship. *Bioorg. Med. Chem. Lett.* 2006, 16, 2539-2542.

32. Wang, T.; Duffy, J.P.; Wang, J.; Halas, S.; Salituro, F.G.; Pierce, A.C.; Zuccola, H.J.; Black, J.R.; Hogan, J.K.; Jepson, S.; Shlyakter, D.; Mahajan, S.; Gu, Y.; Hoock, T.; Wood, M.; Furey, B.F.; Frantz, J.D.; Dauffenbach, L.M.; Germann, U.A.; Fan, B.; Namchuk, M.; Bennani, Y.L.; Ledeboer, M.W. Janus Kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azoindole. *J. Med. Chem.* 2009, 52, 7938-7941.

33. Dinges, J.; Ashworth, K.L.; Akritopolou-Zanze, I.; Arnold, L.D.; Baumeister, S.A.; Bousquet, P.F.; Cunha, G.A.; Davidsen, S.K.; Djuric, S.W.; Gracias, V.J.; Michaelides, M.R.; Rafferty, P.; Sowin, T.J.; Stewart, K.D.; Xia, Z.; Zhang, H.Q. 1,4-dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors. *Bioorg. Med. Chem. Lett.* 2006, 16, 4266-4271.

34. Sem, D.S.; Bertolaet, B.; Baker, B.; Chang, E.; Costache, A.D.; Coutts, S.; Dong, Q.; Hansen, M.; Hong, V.; Huang, X.; Jack, R.M.; Kho, R.; Lang, H.; Ma, C.; Meininger. D.; Pellecchia, M.; Pierre, F.; Villar, H.; Yu, L. Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. *Chem. Biol.* 2004, 11, 185-194.

35. Sheppard,G.S.; Wang, J.; Kawai, M.; Fidanze, S.D.; BaMaung, N.Y.; Erickson, S.A.; Barnes, D.M.; Tedrow, J.S.; Kolaczkowski, L.; Vasudevan, A.; Park, D.C.; Wang, G.T.; Sanders, W.J.; Mantei, R.A.; Palazzo, F.; Tucker-Garcia, L.; Lou, Zhang, P.Q.; Park, C.H.; Kim, K.H.; Petros, A.; Olejniczak, E.; Nettesheim, D.; Hajduk, P.; Henkin, J.; Lesniewski, R.; Davidsen, S.K.; Bell, R.L. Discovery and optimization of anthranillic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. *J. Med. Chem.* 2006, 49, 3822-3849.

36. Borsi, V.; Calderone, V.; Fraga, M.; Luchinat, C.; Sarti, N. Entropic contribution to the linking coefficient in fragment based drug design: a case study. *J. Med. Chem.* 2010, 53, 4285-4289.

37. Nolan, K.A.; Doncaster, J.R.; Dunstan, M.S.; Scott, K.A.; Frenkel, A.D.; Siegel, D.; Ross, D.; Barnes, J.; Levy, C.; Leys, D.; Whitehead, R.C.; Stratford, I.J.; Bryce, R.A. Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinine oxidoreductase-1 (NQO1). *J. Med. Chem.* 2009, 52, 7142-7156.

38. Krier, M.; de Araujo-Junior, J.X.; Schmitt, M.; Duranton, J.; Justiano-Basaran, H.; Lugnier, C.; Bourguignon, J.; Rognan, D. Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor. *J. Med. Chem.* 2005, 48, 3816-3822.
39. Wendt, M.D.; Rockway, T.W.; Geyer, A.; McClellan, W.; Weitzberg, M.; Zhao, X.; Mantei, R.; Nienaber, V.L.; Stewart, K.; Klinghofer, V.; Giranda, V.L. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of n-phenyl amide 6-substitution. *J. Med. Chem.* **2004**, *47*, 303-324.

40. Orita, M.; Ohno, K.; Warizaya, M.; Amano, Y.; Niimi, T. Lead generation and examples: opinion regarding how to follow up hits. *Meth. Enzymol.* **2011**, *493*, 383-419.

41. Fukunishi, Y.; Ono, K.; Orita, M.; Nakamura, H. Selection of in-silico drug screening result by using universal active probes (UAPs), *J. Chem. Inf. Model.* **2010**, *50*, 1233-1240.

42. Rueda, M.; Bottegoni, G.; Abagyan, R. Recipes for the selection of experimental protein conformations for virtual screening. *J. Chem. Inf. Model.* **2010**, *50*, 186-193.

43. Barakat, K.; Mane, J.; Friesen, D.; Tuszynski, J. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. *J. Mol. Graph. Model.* **2010**, *28*, 555-568.

44. Craig, I.R.; Essex, J.; Spiegel, K. Ensemble docking into multiple crystallographically derived protein structures: an evaluation based on the statistical analysis of enrichment. *J. Chem. Inf. Model.* **2010**, *50*, 511-524.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).